Antares Pharma Inc

EWING, N.J.--(BUSINESS WIRE)--Mar 15, 2010 - Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it will release its fourth quarter and full year 2009 financial results after the market closes on Tuesday, March 23, 2010, and host a conference call shortly thereafter at 4:30 p.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, Executive Vice President, Chief Financial Officer and President of the Parenteral Products Division  

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the 22 nd Annual Roth OC Growth Stock Conference on Wednesday, March 17, 2010 at 12:30 p.m. ET (Eastern Time). A live audio webcast of the presentation will be available at http://www.wsw.com/webcast/roth23/ais/ . About Antares Pharma  

The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements. This product has been designed for delivery in a Datapack Format (XLS).  

Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer will present at the Cowen and Company 30 th Annual Health Care Conference on Wednesday, March 10, 2010 at 8:45 a.m. ET (Eastern Time). An audio web cast of the presentation will be available under the investor relations section of the Antares website at www.antarespharma.com . About Antares Pharma Antar  

 

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session. Pluristem Therapeutics ( PSTI Quote ) jumped by 9 cents, or 8%, to $1.22 in the premarket session after the company said it has received approval from an independent Data Safety Monitoring Board (DSMB) to advance to the final dose level with its placenta-derived cell therapy product, PLX-PAD, in a Phase I dose-escalating clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end-s  

 

Antares Pharma, Inc. (NYSE Amex: AIS) announced today that it has completed enrollment in the double-blind portion of the Company’s Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this